Drug Database
TR

triamcinolone benetonide (Benecorten / Curdem / Tibicorten)

✓ Approved

Novartis AG · NR3C1 · Small Molecule

What is triamcinolone benetonide?

triamcinolone benetonide is a small molecule developed by Novartis AG. It is approved for therapeutic indications.

Drug Profile

Brand NamesBenecorten, Curdem, Tibicorten
CompanyNovartis AG
Drug ClassSmall Molecule
Molecular TargetNR3C1
StatusApproved
Sources: ClinicalTrials.gov, Novartis AG

Mechanism of Action

Molecular Targets

triamcinolone benetonide acts on 1 molecular target:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

triamcinolone benetonide is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Skin and subcutaneous tissue disordersDermatitis atopic✓ Approved
Skin and subcutaneous tissue disordersEczema✓ Approved

Related Research Articles

PubMedJournal of molecular histology2026-10-21

Effects of topical vildagliptin versus triamcinolone acetonide on experimentally induced hypertrophic scars in a rabbit model.

Nasser Zaynab Ali ZA, Jaafar Farrah Rasool FR

The present study aimed to evaluate the effects of topical vildagliptin on experimentally induced hypertrophic scars (HTSs) in a rabbit model. A total of 40 healthy male albino rabbits were randomly assigned to five groups (n = 8): healthy control (CTRL), untreated induced HTS model (HTS model), vehicle-received (VEH), 0.1% triamcinolone acetonide-treated (TAC), and 3% vildagliptin-treated (VIL). On day 0, four full-thickness wounds extending to the cartilage were created on the ventral surface of each rabbit ear using an 8-mm biopsy punch. On day 30, topical treatment was initiated on the newly formed scars and continued twice daily for 21 days. Samples were collected on day 51 post-wounding. Outcome measures included molecular quantification of collagen type 1 (Col I), collagen type 3 (Col III), transforming growth factor-beta 1 (TGF-β1), interleukin 6 (IL-6), histopathological examination, and alpha-smooth muscle actin (α-SMA) immunoreactivity. Vildagliptin significantly reduced Col I, Col III, TGF-β1, and IL-6 compared with the HTS model group (p < 0.001). Histopathological analysis revealed a marked improvement in scar architecture, as evidenced by lower histopathological scores and a reduced scar elevation index. Masson's trichrome (MT) staining demonstrated a significant reduction in collagen deposition, accompanied by partial restoration of normal collagen fiber organization. Immunohistochemical analysis revealed no significant change in α-SMA immunoreactivity. This more likely reflects a potential incomplete suppression of myofibroblasts. Overall, these findings suggest that topical vildagliptin may represent a promising therapeutic approach for the treatment of HTSs.

PMID 42902087
Read full article →
PubMedIndian dermatology online journal2026-10-20

Comparison of the Efficacy of Intralesional Methotrexate and Triamcinolone in the Treatment of Nail Psoriasis: A Randomized, Investigator-Blind, Controlled Trial.

Ahmadi Kourosh K, Sepaskhah Mozhdeh M, Bagheri Zahra Z, Radanfar Roya R

Nail psoriasis is a common and challenging-to-treat manifestation of psoriasis. The efficacy of several medications has been studied in treating nail psoriasis with different results. This trial assessed the therapeutic efficacy and safety of intralesional methotrexate injection compared to intralesional triamcinolone injection for nail psoriasis. Seventeen patients (69 nails) were recruited in this investigator-blind, randomized, controlled trial, and 13 patients (65 nails) completed the study. The severity of the disease was evaluated by the modified Nail Psoriasis Severity Index (mNAPSI) before starting treatment, after each injection, and 8 weeks after the last injection. Thirty-three nails were randomly treated with methotrexate and 32 nails with triamcinolone. A volume of 0.1 mL of the diluted (5 mg/mL) triamcinolone (0.5 mg) or 0.05 mL of methotrexate (1.25 mg) was injected at each point every 3 weeks for four sessions. (Clinical trial registry: Iranian Registry of Clinical Trials. [ID: IRCT20140212016557N7]). Both interventions significantly reduced the mNAPSI score ( P < 0.001). The percentage of reduction of mNAPSI score was more in the triamcinolone-treated nails at the end of treatment ( P = 0.015), but not significantly different in the 8-week follow-up ( P = 0.906). Deterioration of the mNAPSI score was seen only in the triamcinolone group at the end of 8 weeks after discontinuation of treatment ( P = 0.01). A relatively small sample size, lack of prolonged follow-up, and absence of response assessment of the nail matrix and bed separately. Intralesional methotrexate is an effective and safe treatment for nail psoriasis, with similar efficacy to intralesional triamcinolone. Methotrexate showed more persistent efficacy compared to triamcinolone.

PMID 42899822
Read full article →
PubMedPain medicine (Malden, Mass.)2026-10-19

Twenty-Eight-Day Pain Trajectories After Standardized Three-Position Coccygeal Infiltration: A Prospective Observational Study of 274 Patients.

Pulido Loreto C LC, Koehl Philipp P, Schuh Alexander A, Benditz Achim A

To characterize daily pain trajectories after standardized three-position coccygeal infiltration and explore differences by clinical and radiographic subgroups. Prospective, single-arm observational cohort study. Specialized orthopedic and spine care setting. Patients had chronic coccygodynia with symptomatic coccygeal instability confirmed clinically and on paired standing and seated lateral radiographs. Of 668 treated patients receiving a diary, 274 returned complete diaries and were analyzed (41.0%); 394 did not return a diary (59.0%). Patients were treated prone without procedural imaging guidance. Through one skin entry, a 23-gauge needle was directed sequentially to the symptomatic mobile segment, coccygeal tip, and immediately lateral to the coccyx. The standard injectate was mepivacaine 1% (5 mL) plus triamcinolone 40 mg. NRS pain was recorded before infiltration (day 0) and daily through post-injection day 27. Responder thresholds were ≥30%, ≥50%, and, supplementarily, ≥2-point improvement. Mean NRS was 5.55 at baseline, increased transiently on post-injection days 1 and 2, and was below baseline on day 3. By day 27, mean NRS was 1.99 (paired change, -3.56; 95% CI, -3.90 to - 3.22; P < 0.001; Cohen dz = 1.24); 220 patients (80.3%) achieved ≥30% improvement and 192 (70.1%) achieved ≥50% improvement. Mean pain decreased further from 3.51 in diary week 3 to 2.73 in diary week 4 (change, -0.78; 95% CI, -0.95 to - 0.61; P < 0.001; Cohen dz = 0.55). More than half of day-20 nonresponders achieved responder status by day 27. Three-position coccygeal infiltration was followed by substantial pain reduction through day 27, including further improvement during diary week 4. Causal efficacy cannot be established without a comparison group, and responder estimates may not represent the entire treated population because 59.0% did not return diaries.

PMID 42895865
Read full article →
PubMedClinical ophthalmology (Auckland, N.Z.)2026-10-18

One-Year Outcomes of PreserFlo MicroShunt implantation Using Intraoperative Sub-Tenon Triamcinolone Acetonide.

Takagi Yuki Y, Shiroyama Shota S, Asano Ryo R, Watanabe Mitsunori M

To evaluate the 1-year efficacy, postoperative intervention burden, and safety of PreserFlo MicroShunt (PMS) implantation using intraoperative sub-Tenon triamcinolone acetonide (STTA). This two-center retrospective study included 107 eyes of 107 consecutive patients who underwent standalone PMS implantation between December 2023 and May 2025. Mitomycin C (0.4 mg/mL) was applied for 5 min, followed by 20 mg STTA. Complete success was defined as an intraocular pressure (IOP) of 6-12 mmHg, with at least a 20% reduction from baseline, without medication or additional surgery. Qualified success allowed the use of glaucoma medications. Needling-free complete success was considered when the first needling procedure failed. Kaplan-Meier analysis was used to estimate success rates, and Cox proportional hazards regression analysis was used to evaluate factors associated with surgical failure. Median preoperative IOP was 22.0 mmHg (interquartile range [IQR], 17.0-28.0), and median medication score was 5.0 (IQR, 4.0-5.0). At 12 months, median IOP decreased to 9.0 mmHg (IQR, 6.0-12.0), and median medication score decreased to 0.0 (IQR, 0.0-0.0; both P<0.001). The estimated 12-month complete, qualified, and needling-free complete success rates were 83.1%, 85.0%, and 67.7%, respectively. Needling was performed in 18 eyes (16.8%), and 16 of those eyes (88.9%) met the complete success criteria at the final assessment within 12 months. Hypotony was present at 1 month in 37 eyes (34.6%), including persistent hypotony in 25 eyes (23.4%). Most hypotony-related events resolved without surgery. One eye developed suprachoroidal hemorrhage with severe visual loss. No significant baseline predictors of failure were identified. This protocol achieved substantial IOP and medication reduction with favorable 12-month success rates. Needling is an important component of postoperative management, and persistent numerical hypotony is common, but usually resolves without surgery. Comparative studies are needed to determine the specific contributions of STTA.

PMID 42893261
Read full article →
PubMedInternational ophthalmology2026-10-16

Non-surgical management of thyroid eye disease: a pilot survey of oculoplastic surgeons.

Hui Shiqi S, Luo Lihua L, Li Dongmei D

To investigate real-world practices in the non-surgical management of thyroid eye disease (TED) among oculoplastic surgeons across participating Asia-Pacific clinical settings. A structured 39-item online questionnaire was distributed between August and October 2023 to 40 eligible oculoplastic surgeons identified through the Asia Pacific Society of Ophthalmic Plastic and Reconstructive Surgery. The questionnaire assessed clinical experience, TED patient volume, and preferred non-surgical therapeutic approaches, including corticosteroids, immunosuppressive agents, orbital radiotherapy (ORT), biologic therapies, periocular injections, and micronutrient supplementation. Descriptive statistics were used because of the exploratory nature and small sample size of the survey. Seventeen physicians completed the questionnaire, corresponding to a response rate of 42.5%. All respondents reported using glucocorticoids, and intravenous methylprednisolone was the predominant systemic treatment. A cumulative dose of 4.5 g, administered as 6 weekly infusions of 500 mg followed by 6 weekly infusions of 250 mg, was selected by 13 respondents (76.5%). Periocular injections were used by 11 respondents (64.7%), with triamcinolone acetonide being the most frequently used agent. Ten respondents (58.8%) reported using ORT. Immunosuppressive agents were used less frequently, with mycophenolate mofetil and methotrexate each reported by 3 respondents (17.7%). Biologic therapies included tocilizumab (4, 23.5%), rituximab (3, 17.7%), and teprotumumab (1, 5.9%). Selenium supplementation was reported only sporadically. This exploratory survey demonstrates substantial variability in the non-surgical management of TED across participating Asia-Pacific settings. Given the small, non-random sample and uneven country representation, these findings should be interpreted as preliminary and hypothesis-generating rather than representative of the Asia-Pacific region as a whole.

PMID 42886427
Read full article →
PubMedNepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH2026-10-14

Management of Adult-onset Eyelid Xanthogranuloma: Debulking Surgery Coupled with Intralesional Corticosteroids.

Kamaluddin Najmatuzzahra N, Pratiwi Andi A

Adult-onset xanthogranuloma (AOX) is a rare, benign inflammatory disorder within the spectrum of non-Langerhans cell histiocytosis, often manifesting as localised skin lesions in middle-aged adults and frequently misdiagnosed due to its nonspecific presentation. A 43-year-old woman developed a painless, progressively enlarging mass on her right upper eyelid over four months, with histopathology confirming AOX. Following surgical debulking and adjunctive intralesional corticosteroid (triamcinolone acetonide) injection, the patient exhibited significant clinical improvement and no recurrence at three months. This outcome supports emerging evidence that a combination of surgery and corticosteroid therapy effectively reduces lesion size and recurrence rates in localised AOX. The multimodal approach combining surgical excision and intralesional corticosteroid injections provides a conservative and effective management strategy for AOX, with favourable outcomes and minimal complications. Further research is warranted to standardise treatment protocols for this rare orbital disease.

PMID 42870477
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about triamcinolone benetonide